Advanced search
Publication Cover
International Journal of Food Properties Volume 26, 2023 - Issue 1
Submit an article Journal homepage
2,403
Views
0
CrossRef citations to date
0
Altmetric
Review

Natural molecules as promising players against diabetic peripheral neuropathy: an emerging nutraceutical approach

Rabia Akrama Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanView further author information
,
Haseeb Anwara Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanView further author information
,
Muhammad Shahid Javedb Department of Physiology, Sargodha Medical College, Sargodhakebri Dehar, PakistanView further author information
,
Ali Imranc Department of Food Sciences, Government College University, Faisalabad, PakistanView further author information
,
Azhar Rasuld Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanView further author information
,
Shoaib Ahmad Malike Department of Biochemistry, Sargodha Medical College, Sargodha, PakistanView further author information
,
Mobina Manzoorf Institute of Pharmacy, Lahore College for Women University, Lahore, PakistanView further author information
,
Fakhar Islamc Department of Food Sciences, Government College University, Faisalabad, PakistanORCID Iconhttps://orcid.org/0000-0001-6935-5924View further author information
ORCID Icon,
Ikram Ullah Khang Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, PakistanView further author information
,
Faiqa Sajida Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanView further author information
,
Tehreem Imana Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanView further author information
,
Muhammad Ajmal Shahh Department of Pharmacy, Hazara University, Mansehra, PakistanView further author information
,
Tao Suni Center for Precision Medicine, School of Medicine and School of Biomedical Sciences, Huaqiao University, Xiamen, Fujian Province, ChinaView further author information
,
Ghulam Hussaina Neurochemicalbiology and Genetics Laboratory (NGL), Department of Physiology, Faculty of Life Sciences, Government College University, Faisalabad, PakistanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9090-7789View further author information
ORCID Icon &
Mohd Asif Shahj Department of Economics, Kebri Dehar University, Kebri Dehar, Ethiopia;k University Centre for Research & Development, University School of Business, Chandigarh University, Mohali, Punjab, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0351-9559View further author information
ORCID Icon show all
Pages 894-914 | Received 29 Nov 2022, Accepted 03 Mar 2023, Published online: 19 Mar 2023

References

  • Kharroubi, A. T. Diabetes Mellitus: The Epidemic of the Century. World J. Diabetes. 2015, 6(6), 850. DOI: 10.4239/wjd.v6.i6.850.
  • Galtier, F. Definition, Epidemiology, Risk Factors. Diabetes. Metab. 2010, 36(6), 628–651. DOI: 10.1016/j.diabet.2010.11.014.
  • Chobanian, A. V.; Bakris, G. L.; Black, H. R.; Cushman, W. C.; Green, L. A.; Izzo, J. L.; Jones, D. W.; Materson, B. J.; Oparil, S.; Wright, J. T., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. J. Am. Med. Assoc. 2003, 289(19), 2560.
  • Aynalem, S. B.; Zeleke, A. J. Prevalence of Diabetes Mellitus and Its Risk Factors Among Individuals Aged 15 Years and Above in Mizan-Aman Town, Southwest Ethiopia, 2016: A Cross Sectional Study. Int. J. Endocrinol. 2018, 2018, 1–7. DOI: 10.1155/2018/9317987.
  • Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A. A.; Ogurtsova, K., et al. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas 9th. Diabetes res. clin. pract. 2019, 157, 107843. DOI: 10.1016/j.diabres.2019.107843.
  • Bellelli, A.; Santi, D.; Simoni, M.; Greco, C. Diabetic Neuropathic Cachexia: A Clinical Case and Review of Literature. Life (Basel, Switzerland). 2022, 12(5). DOI: 10.3390/LIFE12050680.
  • Kasznicki, J. Advances in the Diagnosis and Management of Diabetic Distal Symmetric Polyneuropathy. Arch. Med. Sci. 2014, 2, 345. DOI: 10.5114/AOMS.2014.42588.
  • Mizisin, A. P. Mechanisms of Diabetic Neuropathy: Schwann Cells. Handb. Clin. Neurol.2014, 126, 401–428. DOI: 10.1016/B978-0-444-53480-4.00029-1.
  • Brown, A. M.; Evans, R. D.; Black, J.; Ransom, B. R. Schwann Cell Glycogen Selectively Supports Myelinated Axon Function. Ann. Neurol. 2012, 72(3), 406–418. DOI: 10.1002/ana.23607.
  • Naruse, K. Schwann Cells as Crucial Players in Diabetic Neuropathy. Adv. Exp. Med. Biol. 2019, 1190, 345–356. DOI: 10.1007/978-981-32-9636-7_22.
  • Eckersley, L. Role of the Schwann Cell in Diabetic Neuropathy. Int. Rev. Neurobiol. 2002, 50, 293–321.
  • Gonçalves, N. P.; Vægter, C. B.; Pallesen, L. T. Peripheral Glial Cells in the Development of Diabetic Neuropathy. Front. Neurol. 2018, 9. DOI: 10.3389/fneur.2018.00268.
  • Leinninger, G. M.; Vincent, A. M.; Feldman, E. L. The Role of Growth Factors in Diabetic Peripheral Neuropathy. J. Peripher. Nerv. Syst. 2004, 9(1), 26–53. DOI: 10.1111/j.1085-9489.2004.09105.x.
  • Obrosova, I. G.; Drel, V. R.; Pacher, P.; Ilnytska, O.; Wang, Z. Q.; Stevens, M. J.; Yorek, M. A. Oxidative-Nitrosative Stress and Poly(adp-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation is Revisited. Diabetes. 2005, 54(12), 3435–3441. DOI: 10.2337/diabetes.54.12.3435.
  • Komirishetty, P.; Areti, A.; Gogoi, R.; Sistla, R.; Kumar, A. Poly(adp-Ribose) Polymerase Inhibition Reveals a Potential Mechanism to Promote Neuroprotection and Treat Neuropathic Pain. Neural. Regen. Res. 2016, 11(10), 1545–1548. DOI: 10.4103/1673-5374.193222.
  • Lukic, I. K.; Humpert, P. M.; Nawroth, P. P.; Bierhaus, A. The RAGE Pathway: Activation and Perpetuation in the Pathogenesis of Diabetic Neuropathy. In Proceedings of the Annals of the New York Academy of Sciences; Blackwell Publishing Inc, 2008; Vol. 1126, pp. 76–80.
  • Mišur, I.; Žarković, K.; Barada, A.; Batelja, L.; Miličević, Z.; Turk, Z. Advanced Glycation End Products in Peripheral Nerve in Type 2 Diabetes with Neuropathy. Acta Diabetol. 2004, 41(4), 158–166. DOI: 10.1007/s00592-004-0160-0.
  • Ramana, K. V. Aldose Reductase: New Insights for an Old Enzyme. Biomol. Concepts. 2011, 2(1–2), 103–114. DOI: 10.1515/bmc.2011.002.
  • Alter, M. L.; Ott, I. M.; Von Websky, K.; Tsuprykov, O.; Sharkovska, Y.; Krause-Relle, K.; Raila, J.; Henze, A.; Klein, T.; Hocher, B. DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy. Kidney Blood Press. Res. 2012, 36(1), 119–130. DOI: 10.1159/000341487.
  • Yamagishi, S. I.; Maeda, S.; Matsui, T.; Ueda, S.; Fukami, K.; Okuda, S. Role of Advanced Glycation End Products (AGEs) and Oxidative Stress in Vascular Complications in Diabetes. Biochim. Biophys. Acta - Gen. Subj. 2012, 1820(5), 663–671. DOI: 10.1016/j.bbagen.2011.03.014.
  • Schemmel, K. E.; Padiyara, R. S.; D’souza, J. J. Aldose Reductase Inhibitors in the Treatment of Diabetic Peripheral Neuropathy: A Review. J. Diabetes Complications. 2010, 24(5), 354–360. DOI: 10.1016/j.jdiacomp.2009.07.005.
  • Ho, E. C. M.; Lam, K. S. L.; Yuk, S. C.; Yip, J. C. W.; Arvindakshan, M.; Yamagishi, S. I.; Yagihashi, S.; Oates, P. J.; Ellery, C. A.; Chung, S. S. M., et al. Aldose Reductase–Deficient Mice are Protected from Delayed Motor Nerve Conduction Velocity, Increased C-Jun NH2-Terminal Kinase Activation, Depletion of Reduced Glutathione, Increased Superoxide Accumulation, and DNA Damage. Diabetes. 2006, 55(7), 1946–1953.
  • Steinberg, S. F. Structural Basis of Protein Kinase C Isoform Function. Physiol. Rev. 2008, 88(4), 1341–1378. DOI: 10.1152/physrev.00034.2007.
  • Chandrasekaran, K.; Zilliox, L. A.; Russell, J. W. Diabetic Neuropathy – Research Basic and Translational Research in Diabetic Neuropathy. Microvasc. Dis. Diabetes Hum. 2020, 129–155.
  • Geraldes, P.; King, G. L. Activation of Protein Kinase C Isoforms and Its Impact on Diabetic Complications. Circ. Res. 2010, 106, 1319–1331. DOI: 10.1161/CIRCRESAHA.110.217117.
  • Du, X. L.; Edelstein, D.; Rossetti, L.; Fantus, I. G.; Goldberg, H.; Ziyadeh, F.; Wu, J.; Brownlee, M. Hyperglycemia-Induced Mitochondrial Superoxide Overproduction Activates the Hexosamine Pathway and Induces Plasminogen Activator Inhibitor-1 Expression by Increasing Sp1 Glycosylation. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 12222–12226. DOI: 10.1073/pnas.97.22.12222.
  • Guo, J.; Whittemore, R.; He, G. P. The Relationship Between Diabetes Self-Management and Metabolic Control in Youth with Type 1 Diabetes: An Integrative Review. J. Adv. Nurs. 2011, 67, 2294–2310. DOI: 10.1111/j.1365-2648.2011.05697.x.
  • Francis, G.; Martinez, J.; Liu, W.; Nguyen, T.; Ayer, A.; Fine, J.; Zochodne, D.; Hanson, L. R.; Frey, W. H.; Toth, C. Intranasal Insulin Ameliorates Experimental Diabetic Neuropathy. Diabetes. 2009, 58, 934–945. DOI: 10.2337/db08-1287.
  • Kim, B.; Feldman, E. L. Insulin Resistance in the Nervous System. Trends Endocrinol. Metab. 2012, 23, 133–141. DOI: 10.1016/j.tem.2011.12.004.
  • Eguchi, K.; Manabe, I. Macrophages and Islet Inflammation in Type 2 Diabetes. Diabetes Obes. Metab. 2013, 15, 152–158. DOI: 10.1111/dom.12168.
  • Pop-Busui, R.; Herman, W. H.; Feldman, E. L.; Low, P. A.; Martin, C. L.; Cleary, P. A.; Waberski, B. H.; Lachin, J. M.; Albers, J. W. DCCT and EDIC Studies in Type 1 Diabetes: Lessons for Diabetic Neuropathy Regarding Metabolic Memory and Natural History. Curr. Diab. Rep. 2010, 10, 276–282. DOI: 10.1007/s11892-010-0120-8.
  • Han, J. W.; Sin, M. Y.; Yoon, Y. S. Cell Therapy for Diabetic Neuropathy Using Adult Stem or Progenitor Cells. Diabetes Metab. J. 2013, 37, 91–105. DOI: 10.4093/dmj.2013.37.2.91.
  • Huang, E. J.; Reichardt, L. F. Neurotrophins: Roles in Neuronal Development and Function. Annu. Rev. Neurosci. 2001, 24, 677–736. DOI: 10.1146/annurev.neuro.24.1.677.
  • Kermani, P.; Rafii, D.; Jin, D. K.; Whitlock, P.; Schaffer, W.; Chiang, A.; Vincent, L.; Friedrich, M.; Shido, K.; Hackett, N. R., et al. Neurotrophins Promote Revascularization by Local Recruitment of TrkB+ Endothelial Cells and Systemic Mobilization of Hematopoietic Progenitors. J. Clin. Invest. 2005, 115, 653–663. DOI: 10.1172/jci22655.
  • Khdour, M. R. Treatment of Diabetic Peripheral Neuropathy: A Review. J. Pharm. Pharmacol. 2020, 72, 863–872. DOI: 10.1111/jphp.13241.
  • Snyder, M. J.; Gibbs, L. M.; Lindsay, T. J. Treating Painful Diabetic Peripheral Neuropathy: An Update. Am. Fam. Physician. 2016, 94(3), 227–234.
  • Atef, M.; El-Sayed, N.; Mostafa, Y.; Ahmed, A. Recent Updates in Treatment of Diabetic Neuropathy. Rec. Pharm. Biomed. Sci. 2019, 0, 15–27. DOI: 10.21608/rpbs.2019.12385.1033.
  • Javed, S.; Petropoulos, I. N.; Alam, U.; Malik, R. A. Treatment of Painful Diabetic Neuropathy. Ther. Adv. Chronic Dis. 2015, 6, 15–28. DOI: 10.1177/2040622314552071.
  • Hosseini, A.; Abdollahi, M. Diabetic Neuropathy and Oxidative Stress: Therapeutic Perspectives. OXID. MED. CELL LONGEV. 2013, 2013, 1–15. DOI: 10.1155/2013/168039.
  • Stevens, M.; Shakher, J. Update on the Management of Diabetic Polyneuropathies. Diabetes, Metab. Syndr. Obes. Targets Ther. 2011, 289. DOI: 10.2147/dmso.s11324.
  • Edwards, J. L.; Vincent, A. M.; Cheng, H. T.; Feldman, E. L. Diabetic Neuropathy: Mechanisms to Management. Pharmacol. Ther. 2008, 120, 1–34. DOI: 10.1016/j.pharmthera.2008.05.005.
  • Li, R.; Ma, J.; Wu, Y.; Nangle, M.; Zou, S.; Li, Y.; Yin, J.; Zhao, Y.; Xu, H.; Zhang, H., et al. Dual Delivery of NGF and bFgf Coacervater Ameliorates Diabetic Peripheral Neuropathy via Inhibiting Schwann Cells Apoptosis. Int. J. Biol. Sci. 2017, 13, 640–651. DOI: 10.7150/ijbs.18636.
  • Stavniichuk, R.; Drel, V. R.; Shevalye, H.; Maksimchyk, Y.; Kuchmerovska, T. M.; Nadler, J. L.; Obrosova, I. G. Baicalein Alleviates Diabetic Peripheral Neuropathy Through Inhibition of Oxidative-Nitrosative Stress and P38 MAPK Activation. Exp. Neurol. 2011, 230, 106–113. DOI: 10.1016/j.expneurol.2011.04.002.
  • Kandhare, A. D.; Raygude, K. S.; Ghosh, P.; Ghule, A. E.; Bodhankar, S. L. Neuroprotective Effect of Naringin by Modulation of Endogenous Biomarkers in Streptozotocin Induced Painful Diabetic Neuropathy. Fitoterapia. 2012, 83, 650–659. DOI: 10.1016/j.fitote.2012.01.010.
  • Bachewal, P.; Gundu, C.; Yerra, V. G.; Kalvala, A. K.; Areti, A.; Kumar, A. Morin Exerts Neuroprotection via Attenuation of ROS Induced Oxidative Damage and Neuroinflammation in Experimental Diabetic Neuropathy. BioFactors. 2018, 44, 109–122. DOI: 10.1002/biof.1397.
  • Yang, R.; Li, L.; Yuan, H.; Liu, H.; Gong, Y.; Zou, L.; Li, S.; Wang, Z.; Shi, L.; Jia, T., et al. Quercetin Relieved Diabetic Neuropathic Pain by Inhibiting Upregulated P2X4 Receptor in Dorsal Root Ganglia. J. Cell. Physiol. 2019, 234, 2756–2764. DOI: 10.1002/jcp.27091.
  • Tian, R.; Yang, W.; Xue, Q.; Gao, L.; Huo, J.; Ren, D.; Chen, X. Rutin Ameliorates Diabetic Neuropathy by Lowering Plasma Glucose and Decreasing Oxidative Stress via Nrf2 Signaling Pathway in Rats. Eur. J. Pharmacol. 2016, 771, 84–92. DOI: 10.1016/j.ejphar.2015.12.021.
  • Bao, L.; Li, J.; Zha, D.; Zhang, L.; Gao, P.; Yao, T.; Wu, X. Chlorogenic Acid Prevents Diabetic Nephropathy by Inhibiting Oxidative Stress and Inflammation Through Modulation of the Nrf2/HO-1 and NF-ĸb Pathways. Int. Immunopharmacol. 2018, 54, 245–253. DOI: 10.1016/j.intimp.2017.11.021.
  • Sun, W.; Liu, X.; Zhang, H.; Song, Y.; Li, T.; Liu, X.; Liu, Y.; Guo, L.; Wang, F.; Yang, T., et al. Epigallocatechin Gallate Upregulates NRF2 to Prevent Diabetic Nephropathy via Disabling KEAP1. Free Radic Biol. Med. 2017, 108, 840–857. DOI: 10.1016/j.freeradbiomed.2017.04.365.
  • Ahad, A.; Ganai, A. A.; Mujeeb, M.; Siddiqui, W. A. Ellagic Acid, an NF-Κb Inhibitor, Ameliorates Renal Function in Experimental Diabetic Nephropathy. Chem. Biol. Interact. 2014, 219, 64–75. DOI: 10.1016/j.cbi.2014.05.011.
  • Sharaf El Din, U. A. A.; Mansour Salem, M.; Abdulazim, D. O. Recent Advances in Management of Diabetic Nephropathy. J. Clin. Exp. Nephrol. 2017, 02, 1–22. DOI: 10.21767/2472-5056.100035.
  • Vincent, A. M.; Callaghan, B. C.; Smith, A. L.; Feldman, E. L. Diabetic Neuropathy: Cellular Mechanisms as Therapeutic Targets. Nat. Rev. Neurol. 2011, 7, 573–583. DOI: 10.1038/nrneurol.2011.137.
  • Spallone, V. Management of Painful Diabetic Neuropathy: Guideline Guidance or Jungle? Curr. Diab. Rep. 2012.
  • Chong, M. S.; Hester, J. Diabetic Painful Neuropathy: Current and Future Treatment Options. Drugs. 2007, 67, 569–585. DOI: 10.2165/00003495-200767040-00006.
  • Rudroju, N.; Bansal, D.; Teja Talakokkula, S.; Gudala, K.; Hota, D.; Bhansali, A.; Ghai, B. Comparative Efficacy and Safety of Six Antidepressants and Anticonvulsants in Painful Diabetic Neuropathy: A Network Meta-Analysis. Pain Physician. 2013, 16, E705–14.
  • Baba, M.; Matsui, N.; Kuroha, M.; Wasaki, Y.; Ohwada, S. Mirogabalin for the Treatment of Diabetic Peripheral Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Phase III Study in Asian Patients. J. Diabetes Investig. 2019, 10(5), 1299–1306. DOI: 10.1111/jdi.13013.
  • Tetsunaga, T.; Tetsunaga, T.; Nishida, K.; Misawa, H.; Takigawa, T.; Yamane, K.; Tsuji, H.; Takei, Y.; Ozaki, T. Short-Term Outcomes of Mirogabalin in Patients with Peripheral Neuropathic Pain: A Retrospective Study. J. Orthopaedic Surg Res. 2020, 15, 1–8. DOI: 10.1186/s13018-020-01709-3.
  • Javed, S.; Alam, U.; Malik, R. A. Mirogabalin and Emerging Therapies for Diabetic Neuropathy. J. Pain Res. 2018, Volume 11, 1559–1566. DOI: 10.2147/JPR.S145999.
  • Barbano, R. L.; Herrmann, D. N.; Hart-Gouleau, S.; Pennella-Vaughan, J.; Lodewick, P. A.; Dworkin, R. H. Effectiveness, Tolerability, and Impact on Quality of Life of the 5% Lidocaine Patch in Diabetic Polyneuropathy. Arch. Neurol. 2004, 61, 914. DOI: 10.1001/archneur.61.6.914.
  • Viola, V.; Newnham, H. H.; Simpson, R. W. Treatment of Intractable Painful Diabetic Neuropathy with Intravenous Lignocaine. J. Diabetes Complications. 2006, 20, 34–39. DOI: 10.1016/j.jdiacomp.2005.05.007.
  • Dworkin, R. H.; O’connor, A. B.; Backonja, M.; Farrar, J. T.; Finnerup, N. B.; Jensen, T. S.; Kalso, E. A.; Loeser, J. D.; Miaskowski, C.; Nurmikko, T. J., et al. Pharmacologic Management of Neuropathic Pain: Evidence-Based Recommendations. Pain. 2007, 132, 237–251. DOI: 10.1016/j.pain.2007.08.033.
  • Finnerup, N. B.; Sindrup, S. H.; Jensen; Jensen, T. S. T.S. The Evidence for Pharmacological Treatment of Neuropathic Pain. Pain. 2010, 150, 573–581. DOI: 10.1016/j.pain.2010.06.019.
  • Gimbel, J. S.; Richards, P.; Portenoy, R. K. Controlled-Release Oxycodone for Pain in Diabetic Neuropathy: A Randomized Controlled Trial. Neurology. 2003, 60, 927–934. DOI: 10.1212/01.WNL.0000057720.36503.2C.
  • Chou, R.; Fanciullo, G. J.; Fine, P. G.; Adler, J. A.; Ballantyne, J. C.; Davies, P.; Donovan, M. I.; Fishbain, D. A.; Foley, K. M.; Fudin, J., et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J. Pain. 2009, 10, 113–130.e22. DOI: 10.1016/j.jpain.2008.10.008.
  • Mcnicol, E. D.; Midbari, A.; Eisenberg, E. Opioids for Neuropathic Pain. Cochrane Database Syst. Rev. 2013, 2019. DOI: 10.1002/14651858.CD006146.pub2.
  • Oates, P. J. Polyol Pathway and Diabetic Peripheral Neuropathy. Int. Rev. Neurobiol. 2002, 50, 325–392. DOI: 10.1016/s0074-7742(02)50082-9.
  • R, M.; R, O. Targeting Aldose Reductase for the Treatment of Diabetes Complications and Inflammatory Diseases: New Insights and Future Directions. J. Med. Chem. 2015, 58, 2047–2067. DOI: 10.1021/JM500907A.
  • Chalk, C.; Benstead, T. J.; Moore, F. Aldose Reductase Inhibitors for the Treatment of Diabetic Polyneuropathy. Cochrane Database Syst. Rev. 2007, 2010. DOI: 10.1002/14651858.CD004572.PUB2.
  • Ramirez, M. A.; Borja, N. L. Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy. Pharmacotherapy. 2008, 28, 646–655. DOI: 10.1592/phco.28.5.646.
  • Hotta, N.; Akanuma, Y.; Kawamori, R.; Matsuoka, K.; Oka, Y.; Shichiri, M.; Toyota, T.; Nakashima, M.; Yoshimura, I.; Sakamoto, N., et al. Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy: The 3-Year, Multicenter, Comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006, 29, 1538–1544. DOI: 10.2337/dc05-2370.
  • Jannapureddy, S.; Sharma, M.; Yepuri, G.; Schmidt, A. M.; Ramasamy, R. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications. Front. Endocrinol. (Lausanne). 2021, 12, 78. DOI: 10.3389/FENDO.2021.636267.
  • Oyenihi, A. B.; Ayeleso, A. O.; Mukwevho, E.; Masola, B. Antioxidant Strategies in the Management of Diabetic Neuropathy. Biomed Res. Int. 2015, 2015, 1–15. DOI: 10.1155/2015/515042.
  • Vinik, A. I.; Bril, V.; Kempler, P.; Litchy, W. J.; Tesfaye, S.; Price, K. L.; Bastyr, E. J. Treatment of Symptomatic Diabetic Peripheral Neuropathy with the Protein Kinase C β-Inhibitor Ruboxistaurin Mesylate During a 1-Year, Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Clin. Ther. 2005, 27, 1164–1180. DOI: 10.1016/j.clinthera.2005.08.001.
  • Haupt, E.; Ledermann, H.; Köpcke, W. Benfotiamine in the Treatment of Diabetic Polyneuropathy - a Three-Week Randomized, Controlled Pilot Study (BEDIP Study). Int. J. Clin. Pharmacol. Ther. 2005, 43, 71–77. DOI: 10.5414/CPP43071.
  • Jolivalt, C. G.; Fineman, M.; Deacon, C. F.; Carr, R. D.; Calcutt, N. A. GLP-1 Signals via ERK in Peripheral Nerve and Prevents Nerve Dysfunction in Diabetic Mice. Diabetes Obes. Metab. 2011, 13, 990–1000. DOI: 10.1111/j.1463-1326.2011.01431.x.
  • Le, T. D.; Nguyen, N. P. T.; Tran, H. T. T.; Cong, T. L.; Nguyen, L. H. T.; Nhu, B. D.; Nguyen, S. T.; Ngo, M. V.; Dinh, H. T.; Nguyen, H. T., et al. Diabetic Peripheral Neuropathy Associated with Cardiovascular Risk Factors and Glucagon-Like Peptide-1 Concentrations Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus. Diabetes, Metab. Syndr. Obes. Targets Ther. 2022, 15, 35–44. DOI: 10.2147/DMSO.S344532.
  • Kawanami, D.; Matoba, K.; Sango, K.; Utsunomiya, K. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence. Int. J. Mol. Sci. 2016, 17, 1223. DOI: 10.3390/IJMS17081223.
  • Kawano, T. A Current Overview of Diabetic Neuropathy – Mechanisms, Symptoms, Diagnosis, and Treatment. Peripheral Neuropathy; InTech. 2014. DOI: 10.5772/58308.
  • Schratzberger, P.; Walter, D. H.; Rittig, K.; Bahlmann, F. H.; Pola, R.; Curry, C.; Silver, M.; Krainin, J. G.; Weinberg, D. H.; Ropper, A. H., et al. Reversal of Experimental Diabetic Neuropathy by VEGF Gene Transfer. J. Clin. Invest. 2001, 107, 1083–1092. DOI: 10.1172/JCI12188.
  • Ropper, A. H.; Gorson, K. C.; Gooch, C. L.; Weinberg, D. H.; Pieczek, A.; Ware, J. H.; Kershen, J.; Rogers, A.; Simovic, D.; Schratzberger, P., et al. Vascular Endothelial Growth Factor Gene Transfer for Diabetic Polyneuropathy: A Randomized, Double-Blinded Trial. Ann. Neurol. 2009, 65, 386–393. DOI: 10.1002/ana.21675.
  • Ii, M.; Nishimura, H.; Kusano, K. F.; Qin, G.; Yoon, Y. S.; Wecker, A.; Asahara, T.; Losordo, D. W. Neuronal Nitric Oxide Synthase Mediates Statin-Induced Restoration of Vasa Nervorum and Reversal of Diabetic Neuropathy. Circulation. 2005, 112, 93–102. DOI: 10.1161/CIRCULATIONAHA.104.511964.
  • Tague, S. E.; Smith, P. G. Vitamin D Receptor and Enzyme Expression in Dorsal Root Ganglia of Adult Female Rats: Modulation by Ovarian Hormones. J. Chem. Neuroanat. 2011, 41, 1–12. DOI: 10.1016/j.jchemneu.2010.10.001.
  • Tague, S. E.; Clarke, G. L.; Winter, M. K.; McCarson, K. E.; Wright, D. E.; Smith, P. G. Vitamin D Deficiency Promotes Skeletal Muscle Hypersensitivity and Sensory Hyperinnervation. J. Neurosci. 2011, 31, 13728–13738. DOI: 10.1523/JNEUROSCI.3637-11.2011.
  • Basit, A.; Basit, K. A.; Fawwad, A.; Shaheen, F.; Fatima, N.; Petropoulos, I. N.; Alam, U.; Malik, R. A. Vitamin D for the Treatment of Painful Diabetic Neuropathy. BMJ Open Diabetes Res. Care. 2016, 4, 1–6. DOI: 10.1136/bmjdrc-2015-000148.
  • Solanki, N. D.; Patel, R.; Bhavsar, S. K.; Pandya, D. T.; Solanki, N. D.; Bhavsar, S. K.; Pandya, D. T. NAAS Score: 4.11; IC Value: 74.82. UGC-India Approved J. Phytopharm. 2018, 7, 152–161. DOI: 10.31254/phyto.2018.7209.
  • Liang, Y. Z.; Xie, P.; Chan, K. Quality Control of Herbal Medicines. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2004, 812, 53–70. DOI: 10.1016/S1570-0232(04)00676-2.
  • Hussain, G.; Wang, J.; Rasul, A.; Anwar, H.; Qasim, M.; Zafar, S.; Aziz, N.; Razzaq, A.; Hussain, R.; Aguilar, J. G. D., et al. Current Status of Therapeutic Approaches Against Peripheral Nerve Injuries: A Detailed Story from Injury to Recovery. Int. J. Bio. Sci. 2020, 16, 116–134. DOI: 10.7150/ijbs.35653.
  • Al-Adwani, D. G.; Renno, W. M.; Orabi, K. Y.; D’Mello, S. R. Neurotherapeutic Effects of Ginkgo Biloba Extract and Its Terpene Trilactone, Ginkgolide B, on Sciatic Crush Injury Model: A New Evidence. PLoS One. 2019, 14, e0226626. DOI: 10.1371/journal.pone.0226626.
  • Choi, K. M.; Kim, D. R.; Kim, N. H.; Baik, S. H.; Choi, D. S. The Effect of Ginkgo Biloba Extract on Diabetic Peripheral Neuropathy - a 12 Week, Randomized, Placebo-Controlled, Double-Blind Trial -. Korean Diabetes J. 2001, 24, 375–384.
  • Numan, A.; Masud, F.; Khawaja, K. I.; Khan, F. F.; Qureshi, A. B.; Burney, S.; Ashraf, K.; Ahmad, N.; Yousaf, M. S.; Rabbani, I., et al. Clinical and Electrophysiological Efficacy of Leaf Extract of Gingko Biloba L (Ginkgoaceae) in Subjects with Diabetic Sensorimotor Polyneuropathy. Trop. J. Pharm. Res. 2016, 15, 2137–2145. DOI: 10.4314/tjpr.v15i10.12.
  • da Silva, G. G. P.; Zanoni, J. N.; Buttow, N. C. Neuroprotective Action of Ginkgo Biloba on the Enteric Nervous System of Diabetic Rats. World J. Gastroenterol. 2011, 17, 898–905. DOI: 10.3748/wjg.v17.i7.898.
  • Cheung, Z. H.; So, K. F.; Lu, Q.; Yip, H. K.; Wu, W.; Shan, J. J.; Pang, P. K. T.; Chen, C. F. Enhanced Survival and Regeneration of Axotomized Retinal Ganglion Cells by a Mixture of Herbal Extracts. J. Neurotrauma. 2002, 19, 369–378. DOI: 10.1089/089771502753594936.
  • Carla, L.; Schneider, L.; Perez, G. G.; Banzi, S. R.; Zanoni, J. N.; Raquel, M.; Natali, M.; Buttow, N. C. Evaluation of the Effect of Ginkgo Biloba Extract (EGb 761) on the Myenteric Plexus of the Small Intestine of Wistar Rats. J. Gastroenterol. 2007, 42, 624–630. DOI: 10.1007/S00535-007-2079-Z.
  • Kim, J.; Yokoyama, K.; Araki, S. The Effects of Ginkgo Biloba Extract (GBe) on Axonal Transport Microvasculature and Morphology of Sciatic Nerve in Streptozotocin-Induced Diabetic Rats. Environ. Health Prev. Med. 2000, 5, 53–59. DOI: 10.1007/bf02932004.
  • Pottathil, S.; Nain, P.; Morsy, M. A.; Kaur, J.; Al-Dhubiab, B. E.; Jaiswal, S.; Nair, A. B. Mechanisms of Antidiabetic Activity of Methanolic Extract of Punica Granatum Leaves in Nicotinamide/streptozotocin-Induced Type 2 Diabetes in Rats. Plants. 2020, 9, 1–15. DOI: 10.3390/plants9111609.
  • Guerrero-Solano, J. A.; Jaramillo-Morales, O. A.; Velázquez-González, C.; De la O-Arciniega, M.; Castañeda-Ovando, A.; Betanzos-Cabrera, G.; Bautista, M. Pomegranate as a Potential Alternative of Pain Management: A Review. Plants. 2020, 9, 1–18. DOI: 10.3390/plants9040419.
  • Li, Y.; Wen, S.; Kota, B. P.; Peng, G.; Li, G. Q.; Yamahara, J.; Roufogalis, B. D. Punica Granatum Flower Extract, a Potent α-Glucosidase Inhibitor, Improves Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats. J. Ethnopharmacol. 2005, 99, 239–244. DOI: 10.1016/j.jep.2005.02.030.
  • Raafat, K.; Samy, W. Amelioration of Diabetes and Painful Diabetic Neuropathy by Punica Granatum L. Extract and Its Spray Dried Biopolymeric Dispersions. Evidence-Based Complement. Altern. Med. 2014, 2014, 1–12. DOI: 10.1155/2014/180495.
  • Nazma Yesmin, M.; Sarder Nasir Uddin, S. M.; Akond, M. A. Antioxidant and Antibacterial Activities of. Society. 2005, 28, 2225–2230.
  • Ahmad, M. B.; Gwarzo, M. Y.; Anwar, S. Antioxidative and Anti-Hyperglycaemic Effect of Calotropis Procera in Alloxan Induced Diabetic Rats. J. Med. Plants Res. 2016, 10, 54–58. DOI: 10.5897/jmpr2014.5704.
  • Zafar, S.; Rasul, A.; Iqbal, J.; Anwar, H.; Imran, A.; Jabeen, F.; Shabbir, A.; Akram, R.; Maqbool, J.; Sajid, F., et al. Calotropis Procera (Leaves) Supplementation Exerts Curative Effects on Promoting Functional Recovery in a Mouse Model of Peripheral Nerve Injury. Food Sci. Nutr. 2021, 9(9), 2455.
  • Zafar, S.; Anwar, H.; Qasim, M.; Irfan, S.; Maqbool, J.; Sajid, F.; Naqvi, S. A. R.; Hussain, G. Calotropis Procera (Root) Escalates Functions Rehabilitation and Attenuates Oxidative Stress in a Mouse Model of Peripheral Nerve Injury. Pak. J. Pharm. Sci. 2020, 33, 2801–2807.
  • Neto, M. C. L.; de Vasconcelos, C. F. B.; Thijan, V. N.; Caldas, G. F. R.; Araújo, A. V.; Costa-Silva, J. H.; Amorim, E. L. C.; Ferreira, F.; de Oliveira, A. F. M.; Wanderley, A. G. Evaluation of Antihyperglycaemic Activity of Calotropis Procera Leaves Extract on Streptozotocin-Induced Diabetes in Wistar Rats. Brazilian J. Pharmacogn. 2013, 23, 913–919. DOI: 10.1590/S0102-695X2013000600008.
  • Yadav, S. K.; Nagori, B. P.; Desai, P. K. Pharmacological Characterization of Different Fractions of Calotropis Procera (Asclepiadaceae) in Streptozotocin Induced Experimental Model of Diabetic Neuropathy. J. Ethnopharmacol. 2014, 152, 349–357. DOI: 10.1016/j.jep.2014.01.020.
  • Thaifa, M. S.; Roshna, N.; Arya, U. S.; Babu, A. G. A Review on Diabetes Mellitus and Diabetic Neuropathy: A Plant Based Approach. J. Pharmacogn. Phytochem. 2017, 6, 506–510.
  • Ghazanfar, K.; Ganai, B. A.; Akbar, S.; Mubashir, K.; Dar, S. A.; Dar, M. Y.; Tantry, M. A. Antidiabetic Activity of Artemisia Amygdalina Decne in Streptozotocin Induced Diabetic Rats. Biomed Res. Int. 2014, 2014, 1–10. DOI: 10.1155/2014/185676.
  • Wang, Z. Q.; Ribnicky, D.; Zhang, X. H.; Zuberi, A.; Raskin, I.; Yu, Y.; Cefalu, W. T. An Extract of Artemisia Dracunculus L. Enhances Insulin Receptor Signaling and Modulates Gene Expression in Skeletal Muscle in KK-Ay Mice. J. Nutr Biochem. 2011, 22, 71–78. DOI: 10.1016/j.jnutbio.2009.11.015.
  • Watcho, P.; Stavniichuk, R.; Tane, P.; Shevalye, H.; Maksimchyk, Y.; Pacher, P.; Obrosova, I. G. Evaluation of PMI-5011, an Ethanolic Extract of Artemisia Dracunculus L., on Peripheral Neuropathy in Streptozotocin-Diabetic Mice. Int. J. Mol. Med. 2011, 27, 299–307. DOI: 10.3892/ijmm.2011.597.
  • Watcho, P.; Stavniichuk, R.; Ribnicky, D. M.; Raskin, I.; Obrosova, I. G. High-Fat Diet-Induced Neuropathy of Prediabetes and Obesity: Effect of PMI-5011, an Ethanolic Extract of Artemisia Dracunculus L. Mediators Inflamm. 2010, 2010, 1–10. DOI: 10.1155/2010/268547.
  • Shane-McWhorter, L. Dietary Supplements for Diabetes: An Evaluation of Commonly Used Products. Diabetes Spectr. 2009, 22, 206–213. DOI: 10.2337/diaspect.22.4.206.
  • Raju, M. G.; Satyanarayana, S.; Kumar, E. Safety of Gliclazide with the Aqueous Extract of Gymnema Sylvestre on Pharmacodynamic Activity in Normal and Alloxan Induced Diabetic Rats. Am. J. Phytomed. Clin. Ther. 2014, 2, 901–909.
  • Fatani, A. J.; Al-Rejaie, S. S.; Abuohashish, H. M.; Al-Assaf, A.; Parmar, M. Y.; Ola, M. S.; Ahmed, M. M. Neuroprotective Effects of Gymnema Sylvestre on Streptozotocin-Induced Diabetic Neuropathy in Rats. Exp. Ther. Med. 2015, 9, 1670–1678. DOI: 10.3892/etm.2015.2305.
  • Lingumpelly, R.; Jytothirmaye, P.; Naveen Kumar, G.; Ravi Kumar, M. Anti Diabetic Neuropathy and Pharmacological Evaluation of the Indian Traditional Herb Gymnema Sylvestre. Int. J. Toxicol. Pharmacol. Res. 2015, 7, 60–64.
  • Jain, V.; Pareek, A.; Ratan, Y.; Singh, N. Standardized Fruit Extract of Momordica Charantia L Protect Against Vincristine Induced Neuropathic Pain in Rats by Modulating GABAergic Action, Antimitotoxic, NOS Inhibition, Anti-Inflammatory and Antioxidative Activity. South African J. Bot. 2015, 97, 123–132. DOI: 10.1016/j.sajb.2014.12.010.
  • Malik, Z. A.; Singh, M.; Sharma, P. L. Neuroprotective Effect of Momordica Charantia in Global Cerebral Ischemia and Reperfusion Induced Neuronal Damage in Diabetic Mice. J. Ethnopharmacol. 2011, 133, 729–734. DOI: 10.1016/j.jep.2010.10.061.
  • Malik, Z. A.; Tabassum, N.; Sharma, P. L. Attenuation of Experimentally Induced Diabetic Neuropathy in Association with Reduced Oxidative-Nitrosative Stress by Chronic Administration of Momordica Charantia. Adv. Biosci. Biotechnol. 2013, 04, 356–363. DOI: 10.4236/abb.2013.43047.
  • Mahmood, K. T.; Mugal, T.; Haq, I. U. Moringa Oleifera: A Natural Gift-A Review. J. Pharm. Sci. Res. 2010, 2, 775–781.
  • Razzaq, A.; Ahmad Malik, S.; Saeed, F.; Imran, A.; Rasul, A.; Qasim, M.; Zafar, S.; Kamran, S. K. S.; Maqbool, J.; Imran, M., et al. Moringa Oleifera Lam.Ameliorates the Muscles Function Recovery Following an Induced Insult to the Sciatic Nerve in a Mouse Model. Food Sci. Nutr. 2020, 8, 1–8. DOI: 10.1002/fsn3.1620.
  • Khongrum, J.; Wattanathorn, J.; Muchimapura, S.; Thukhum-Mee, W.; Thipkaew, C.; Wannanon, P.; Tong-Un, T. Moringa Oleifera Leaves Extract Attenuates Neuropathic Pain Induced by Chronic Constriction Injury. Am. J. Appl. Sci. 2012. DOI: 10.3844/ajassp.2012.1182.1187.
  • Raafat, K.; Hdaib, F. Neuroprotective Effects of Moringa Oleifera: Bio-Guided GC-MS Identification of Active Compounds in Diabetic Neuropathic Pain Model. Chin. J. Integr. Med. 2017. DOI: 10.1007/s11655-017-2758-4.
  • Zahara, K. Clinical and Therapeutic Benefits of Centella Asiatica. Pure Appl. Biol. 2014, 3, 152–159. DOI: 10.19045/bspab.2014.34004.
  • Lou, J. -S.; Dimitrova, D. M.; Murchison, C.; Arnold, G. C.; Belding, H.; Seifer, N.; Le, N.; Andrea, S. B.; Gray, N. E.; Wright, K. M., et al. Centella Asiatica Triterpenes for Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Study. Esperienze dermatologiche. 2018, 20. DOI: 10.23736/S1128-9155.18.00455-7.
  • Khan, M. Y.; Panchal, S.; Vyas, N.; Butani, A.; Kumar, V. Olea Europaea: A Phyto-Pharmacological Review. Pharmacogn. Rev. 2007, 1(1), 114–118.
  • Guex, C. G.; Reginato, F. Z.; de Jesus, P. R.; Brondani, J. C.; Lopes, G. H. H.; Bauermann, L. D. F. Antidiabetic Effects of Olea Europaea L. Leaves in Diabetic Rats Induced by High-Fat Diet and Low-Dose Streptozotocin. J. Ethnopharmacol. 2019, 235, 1–7. DOI: 10.1016/j.jep.2019.02.001.
  • Kaeidi, A.; Esmaeili-Mahani, S.; Sheibani, V.; Abbasnejad, M.; Rasoulian, B.; Hajializadeh, Z.; Afrazi, S. Olive (Olea Europaea L.) Leaf Extract Attenuates Early Diabetic Neuropathic Pain Through Prevention of High Glucose-Induced Apoptosis: In vitro and in vivo Studies. J. Ethnopharmacol. 2011, 136, 188–196. DOI: 10.1016/j.jep.2011.04.038.
  • Spandana, U.; Ali, S. L.; Nirmala, T.; Santhi, M.; Sipai Babu, S. D. A Review on Tinospora Cordifolia. Int. J. Curr. Pharm. Rev. Res. 2013, 4(2), 61–68.
  • Nadig, P.; Aliyar, R.; Dethe, S.; Narayanswamy, S.; Revankar, M. Effect of Tinospora Cordifolia on Experimental Diabetic Neuropathy. Indian J. Pharmacol. 2012, 44, 580. DOI: 10.4103/0253-7613.100380.
  • Zangiabadi, N.; Asadi-Shekaari, M.; Sheibani, V.; Jafari, M.; Shabani, M.; Asadi, A. R.; Tajadini, H.; Jarahi, M. Date Fruit Extract is a Neuroprotective Agent in Diabetic Peripheral Neuropathy in Streptozotocin-Induced Diabetic Rats: A Multimodal Analysis. OXID. MED. CELL LONGEV. 2011, 2011, 1–9. DOI: 10.1155/2011/976948.
  • Mia, M. A. T.; Mosaib, M. G.; Khalil, M. I.; Islam, M. A.; Gan, S. H. Potentials and Safety of Date Palm Fruit Against Diabetes: A Critical Review. Foods. 2020, 9, 1–21. DOI: 10.3390/foods9111557.
  • Heydari, M.; Homayouni, K.; Hashempur, M. H.; Shams, M. Topical Citrullus Colocynthis (Bitter Apple) Extract Oil in Painful Diabetic Neuropathy: A Double-Blind Randomized Placebo-Controlled Clinical Trial. J. Diabetes. 2016, 8, 246–252. DOI: 10.1111/1753-0407.12287.
  • Hussain, A. I.; Rathore, H. A.; Sattar, M. Z. A.; Chatha, S. A. S.; Sarker, S. D.; Gilani, A. H. Citrullus Colocynthis (L.) Schrad (Bitter Apple Fruit): A Review of Its Phytochemistry, Pharmacology, Traditional Uses and Nutritional Potential. J. Ethnopharmacol. 2014, 155, 54–66. DOI: 10.1016/j.jep.2014.06.011.
  • Ostovar, M.; Akbari, A.; Anbardar, M. H.; Iraji, A.; Salmanpour, M.; Hafez Ghoran, S.; Heydari, M.; Shams, M. Effects of Citrullus Colocynthis L. in a Rat Model of Diabetic Neuropathy. J. Integr. Med. 2020, 18, 59–67. DOI: 10.1016/j.joim.2019.12.002.
  • Cardoso, A. L. B. D.; Frederico, É. H. F. F.; Guimarães, C. A. S.; Moura-Fernandes, M. C.; Guedes-Aguiar, E. O.; da Silva, A. L. P.; Reis-Silva, A.; Francisca-Santos, A.; de Souza, L. F. F.; Mendonça-Guimarães, R., et al. Effects of Coriandrum Sativum L. in Association with Physical Exercise in Alloxan-Induced Type 1 Diabetes Mellitus in Rats. Appl. Sci. 2019, 9, 5409. DOI: 10.3390/app9245409.
  • Kajal, A.; Singh, R. Coriandrum Sativum Seeds Extract Mitigate Progression of Diabetic Nephropathy in Experimental Rats via AGEs Inhibition. PLoS One. 2019, 14, e0213147. DOI: 10.1371/journal.pone.0213147.
  • Kajal, A.; Singh, R. Coriandrum Sativum Improve Neuronal Function via Inhibition of Oxidative/Nitrosative Stress and TNF-α in Diabetic Neuropathic Rats. J. Ethnopharmacol. 2020, 263, 112959. DOI: 10.1016/j.jep.2020.112959.
  • Anjaneyulu, M.; Chopra, K. Quercetin, a Bioflavonoid, Attenuates Thermal Hyperalgesia in a Mouse Model of Diabetic Neuropathic Pain. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003, 27, 1001–1005. DOI: 10.1016/S0278-5846(03)00160-X.
  • Je, H. D.; Shin, C. Y.; Park, S. Y.; Yim, S. H.; Kum, C.; Huh, I. H.; Kim, J. H.; Sohn, U. D. Combination of Vitamin C and Rutin on Neuropathy and Lung Damage of Diabetes Mellitus Rats. Arch. Pharm. Res. 2002, 25, 184–190. DOI: 10.1007/BF02976561.
  • Dodda, D.; Ciddi, V. Plants Used in the Management of Diabetic Complications. Indian J. Pharm. Sci. 2014, 76, 97.
  • Maqbool, J.; Anwar, H.; Rasul, A.; Imran, A.; Saadullah, M.; Malik, S. A.; Shabbir, A.; Akram, R.; Sajid, F.; Zafar, S., et al. Comparative Evaluation of Ethyl Acetate and N-Hexane Extracts of Cannabis Sativa L. Leaves for Muscle Function Restoration After Peripheral Nerve Lesion. Food Sci. Nutr. 2023, 00, 1–9. DOI: 10.1002/fsn3.3255.
  • Islam, F.; Amer Ali, Y.; Imran, A.; Afzaal, M.; Zahra, S. M.; Fatima, M.; Saeed, F.; Usman, I.; Shehzadi, U.; Mehta, S., et al. Vegetable Proteins as Encapsulating Agents: Recent Updates and Future Perspectives. Food Sci. Nutr. 2023, 00, 1–13. DOI: 10.1002/fsn3.3234.
  • Bagdas, D.; Cinkilic, N.; Ozboluk, H. Y.; Ozyigit, M. O.; Gurun, M. S. Antihyperalgesic Activity of Chlorogenic Acid in Experimental Neuropathic Pain. J. Nat. Med. 2013, 67, 698–704. DOI: 10.1007/s11418-012-0726-z.
  • Baluchnejadmojarad, T.; Roghani, M. Chronic Epigallocatechin-3-Gallate Ameliorates Learning and Memory Deficits in Diabetic Rats via Modulation of Nitric Oxide and Oxidative Stress. Behav. Brain Res. 2011, 224, 305–310. DOI: 10.1016/j.bbr.2011.06.007.
  • Uzar, E.; Alp, H.; Cevik, M. U.; Firat, U.; Evliyaoglu, O.; Tufek, A.; Altun, Y. Ellagic Acid Attenuates Oxidative Stress on Brain and Sciatic Nerve and Improves Histopathology of Brain in Streptozotocin-Induced Diabetic Rats. Neurol. Sci. 2012, 33, 567–574. DOI: 10.1007/s10072-011-0775-1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.